Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kaleido Biosciences's share price for the quarter that ended in Dec. 2021 was $2.39. Kaleido Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2021 was 42.60 Mil. Therefore, Kaleido Biosciences's market cap for the quarter that ended in Dec. 2021 was $101.80 Mil.
Kaleido Biosciences's quarterly market cap
declined
from Jun. 2021 ($316.73 Mil) to Sep. 2021 ($232.49 Mil) and
declined
from Sep. 2021 ($232.49 Mil) to Dec. 2021 ($101.80 Mil).
Kaleido Biosciences's annual market cap
increased
from Dec. 2019 ($151.24 Mil) to Dec. 2020 ($327.81 Mil) but then
declined
from Dec. 2020 ($327.81 Mil) to Dec. 2021 ($101.80 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kaleido Biosciences's Enterprise Value for Today is $-16.78 Mil.
Kaleido Biosciences (OTCPK:KLDO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kaleido Biosciences Market Cap Related Terms
Kaleido Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Kaleido Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kaleido Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaleido Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Kaleido Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kaleido Biosciences's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaleido Biosciences (KLDO) has a Market Cap of $0.00 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Market Cap too high?
Kaleido Biosciences' current Market Cap is $0.00 Mil.
How does Kaleido Biosciences' Market Cap compare to NPTX and GSTC?
Kaleido Biosciences' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kaleido Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaleido Biosciences's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Market Cap is $0.00 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLDO has been successfully added to your 